WO2000024869A3 - Methodes de modulation de fusion cellulaire - Google Patents

Methodes de modulation de fusion cellulaire Download PDF

Info

Publication number
WO2000024869A3
WO2000024869A3 PCT/US1999/024838 US9924838W WO0024869A3 WO 2000024869 A3 WO2000024869 A3 WO 2000024869A3 US 9924838 W US9924838 W US 9924838W WO 0024869 A3 WO0024869 A3 WO 0024869A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell fusion
methods
fusion
mfr
modulation
Prior art date
Application number
PCT/US1999/024838
Other languages
English (en)
Other versions
WO2000024869A2 (fr
WO2000024869A9 (fr
Inventor
Agnes Vignery
Original Assignee
Univ Yale
Agnes Vignery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Agnes Vignery filed Critical Univ Yale
Priority to AU12242/00A priority Critical patent/AU1224200A/en
Publication of WO2000024869A2 publication Critical patent/WO2000024869A2/fr
Publication of WO2000024869A9 publication Critical patent/WO2000024869A9/fr
Publication of WO2000024869A3 publication Critical patent/WO2000024869A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de manière générale la modulation de la fusion cellulaire par modification de la fonction et/ou de l'expression des protéines de surface cellulaire. L'invention porte en particulier sur la modulation du récepteur de fusion des macrophages (MFR) ou du CD44 permettant de modifier la fusion cellulaire. Des méthodes sont décrites pour l'identification d'agents responsables de la modification de la fusion cellulaire par la modulation du MFR ou du CD44. L'invention propose des méthodes qui sont utiles pour le traitement d'états pathologiques associés à la fusion cellulaire modifiée. Les états pathologiques pouvant être traités par les méthodes selon l'invention comprennent des modifications de processus physiologiques qui sont à l'origine d'infections virales, de la résorption osseuse, du développement musculaire et de la fertilisation.
PCT/US1999/024838 1998-10-23 1999-10-22 Methodes de modulation de fusion cellulaire WO2000024869A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU12242/00A AU1224200A (en) 1998-10-23 1999-10-22 Methods for modulating cell fusion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15738798P 1998-10-23 1998-10-23
US60/157,387 1998-10-23

Publications (3)

Publication Number Publication Date
WO2000024869A2 WO2000024869A2 (fr) 2000-05-04
WO2000024869A9 WO2000024869A9 (fr) 2005-02-10
WO2000024869A3 true WO2000024869A3 (fr) 2007-08-23

Family

ID=22563509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/024838 WO2000024869A2 (fr) 1998-10-23 1999-10-22 Methodes de modulation de fusion cellulaire

Country Status (2)

Country Link
AU (1) AU1224200A (fr)
WO (1) WO2000024869A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930706D0 (en) * 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
PL3307065T3 (pl) * 2015-06-11 2024-02-19 The Board Of Trustees Of The University Of Illinois Komórki chimeryczne związane z dystrofią mięśniową i sposób leczenia dystrofii mięśniowych
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
SG11202000658PA (en) 2017-07-26 2020-02-27 Forty Seven Inc Anti-sirp-alpha antibodies and related methods
CN108567973B (zh) * 2017-10-17 2021-03-19 中国科学院深圳先进技术研究院 一种胎盘样硫酸软骨素a免疫组合物及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KLUEG K M, PARODY T R, MUSKAVITCH M A T, AMERICAN SOCIETY FOR CELL BIOLOGY ANNUAL MEETING., XX, XX, 1 December 1997 (1997-12-01), XX, pages 413 + 01, XP002926946 *
SAGINARIO ET AL.: "Identification of an Inducible Surface Molecule Specific to Fusing Macrophages", PROC. NATL. ACAD. SCI. USA,, vol. 92, December 1995 (1995-12-01), pages 12210 - 12214, XP002926947 *
SAGINARIO ET AL.: "MFR, a Putative Receptor Mediating the Fusion of Macrophages", MOLECULAR AND CELLULAR BIOLOGY,, vol. 18, no. 11, November 1998 (1998-11-01), pages 6213 - 6223, XP002926948 *
STERLING ET AL.: "CD44 Occupancy Prevents Macrophage Multinucleation", THE JOURNAL OF CELL BIOLOGY,, vol. 143, no. 3, November 1998 (1998-11-01), pages 837 - 847, XP002926949 *
STERLING H, SAGINARIO C, VIGNERY A: "CD44 OCCUPANCY PREVENTS THE FUSION OF MACROPHAGES", AMERICAN SOCIETY FOR CELL BIOLOGY ANNUAL MEETING., XX, XX, vol. 08, 1 December 1997 (1997-12-01), XX, pages 413 + 01, XP002926945 *

Also Published As

Publication number Publication date
WO2000024869A2 (fr) 2000-05-04
WO2000024869A9 (fr) 2005-02-10
AU1224200A (en) 2000-05-15

Similar Documents

Publication Publication Date Title
AU2002366641A1 (en) Methods for inhibiting ocular processes
EP1507005A3 (fr) Modulation antisens de l'expression du gène BCL-X
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
WO2002099075A3 (fr) Prmt comme modificateurs de la voie p53 et methodes d'utilisation
BR9911396A (pt) Estabilização de enzima por meio de tensoativos catiÈnicos
ZA993364B (en) Novel 4-phenylpiperidines for the treatment of pruritic dermatoses.
DE1082412T1 (de) Transfizierte zellen und methoden zur behandlung von diabetes
MX2009006685A (es) Antagonistas del dr6 y usos de los mismos en el tratamiento de trastornos neurologicos.
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
WO2000024869A3 (fr) Methodes de modulation de fusion cellulaire
DE69924738D1 (de) Modulierung von mlk- (multiple lineage kinase) proteinen
EP1131107A4 (fr) Modulation antisens de l'expression de kappa b kinase alpha inhibitrice
EP1131332A4 (fr) Modulation antisens de l'expression de la kappa b kinase beta inhibitrice
WO1999049038A3 (fr) Proteines de fixation du calcium humaines
WO2003066821A3 (fr) Molecules interagissant avec des polynucleotides et polypeptides casl (mical), et procedes d'utilisation associes
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
EP1582224A4 (fr) Procede de traitement de tissu biologique par irradiation par hyperfrequences
BR9811643A (pt) Suplementação quìmica de osso
EP1255110A3 (fr) Méthodes et produits pour l'identification de modulateurs de l'activité des récepteurs P2X7, et leur utilisation pour le traitement des affections squelettiques
EP1363528A4 (fr) Methodes de diagnostic et de traitement des cardiopathies
DE19983519T1 (de) Vorrichtung zur Wärmebehandlung von Körpergewebe
WO2004082610A3 (fr) Modulation d'une interaction de hyaluronane et de cd44, et leurs utilisations dans le traitement de troubles
WO2003028536A3 (fr) Methodes permettant de diagnostiquer et de traiter les maladies cardiaques
NZ514691A (en) Method to type prion proteins
BR9915317A (pt) Método de tratar trombocitopenia induzida por heparina

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 12242

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09830169

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
COP Corrected version of pamphlet

Free format text: PAGES 1-13, SEQUENCE LISTING, ADDED